[go: up one dir, main page]

PT4215527T - Composições e métodos para tratar a degradação retinal - Google Patents

Composições e métodos para tratar a degradação retinal

Info

Publication number
PT4215527T
PT4215527T PT231612516T PT23161251T PT4215527T PT 4215527 T PT4215527 T PT 4215527T PT 231612516 T PT231612516 T PT 231612516T PT 23161251 T PT23161251 T PT 23161251T PT 4215527 T PT4215527 T PT 4215527T
Authority
PT
Portugal
Prior art keywords
compositions
methods
treating retinal
retinal degradation
degradation
Prior art date
Application number
PT231612516T
Other languages
English (en)
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of PT4215527T publication Critical patent/PT4215527T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT231612516T 2015-02-26 2016-02-26 Composições e métodos para tratar a degradação retinal PT4215527T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121379P 2015-02-26 2015-02-26
US201562246455P 2015-10-26 2015-10-26
US201562247099P 2015-10-27 2015-10-27

Publications (1)

Publication Number Publication Date
PT4215527T true PT4215527T (pt) 2025-01-07

Family

ID=56789808

Family Applications (2)

Application Number Title Priority Date Filing Date
PT231612516T PT4215527T (pt) 2015-02-26 2016-02-26 Composições e métodos para tratar a degradação retinal
PT167564772T PT3261644T (pt) 2015-02-26 2016-02-26 Composições e métodos para tratar a degradação retinal

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT167564772T PT3261644T (pt) 2015-02-26 2016-02-26 Composições e métodos para tratar a degradação retinal

Country Status (13)

Country Link
US (1) US10294220B2 (pt)
EP (3) EP4215527B1 (pt)
JP (1) JP6691922B2 (pt)
KR (2) KR102469789B1 (pt)
AU (3) AU2016225037B2 (pt)
CA (1) CA2976537C (pt)
DK (1) DK3261644T3 (pt)
ES (2) ES3010307T3 (pt)
FI (1) FI4215527T3 (pt)
HR (1) HRP20211050T1 (pt)
PL (1) PL3261644T3 (pt)
PT (2) PT4215527T (pt)
WO (1) WO2016138425A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9326983B2 (en) 2013-08-01 2016-05-03 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
FR3027804A1 (fr) * 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
US11219623B2 (en) 2015-02-26 2022-01-11 University Of Kentucky Research Foundation Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis
WO2019074884A2 (en) * 2017-10-10 2019-04-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY
CN111670032A (zh) 2018-01-31 2020-09-15 欧拉泰克治疗有限责任公司 预防或治疗阿尔茨海默氏病的方法
US12121530B2 (en) * 2018-05-11 2024-10-22 Rhode Island Hospital Composition and methods for treating articulating joint disorders with nucleoside reverse transcriptase inhibitors
US20210348164A1 (en) * 2018-10-09 2021-11-11 University Of Virginia Patent Foundation Endogenous cytoplasmic alu complementary dna in age-related macular degeneration
SG11202107145SA (en) * 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021041317A1 (en) * 2019-08-23 2021-03-04 University Of Virginia Patent Foundation Ddx17 and nlrc4 targeting for inflammatory diseases
US20230172962A1 (en) * 2020-03-20 2023-06-08 University Of Virginia Patent Foundation Nrtis, nrti metabolites, and nrti analogs for macular degeneration and viral infections
CA3184151A1 (en) * 2020-06-29 2022-01-06 Chris Murphy Probenecid compounds for the treatment of inflammasome-mediated lung disease
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
WO2024123982A1 (en) * 2022-12-07 2024-06-13 University Of Virginia Patent Foundation Inflammasome and vegf inhibition for retinal vascular diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63250396A (ja) * 1987-04-03 1988-10-18 Taiho Yakuhin Kogyo Kk 3′−アジド−3′−デオキシチミジン誘導体
ZA886890B (en) * 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
EP0355031A3 (de) * 1988-08-17 1990-12-27 MATTHES, Eckart, Dr. Substituierte Pyrimidinnucleoside, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20100226931A1 (en) * 2004-06-24 2010-09-09 Nicholas Valiante Compounds for immunopotentiation
US8809517B2 (en) 2010-06-01 2014-08-19 University Of Kentucky Research Foundation Method of inhibiting Alu RNA and therapeutic uses thereof
PT3366302T (pt) 2011-07-18 2022-03-07 Univ Kentucky Res Found Proteção de células da degeneração induzida por rna alu e inibidores para proteger as células
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
WO2014160336A1 (en) 2013-03-13 2014-10-02 University Of Kentucky Research Foundation METHODS OF ADMINISTERING IgG1 ANTIBODIES AND METHODS OF SUPPRESSING ANGIOGENESIS
US9326983B2 (en) * 2013-08-01 2016-05-03 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation

Also Published As

Publication number Publication date
EP3261644A1 (en) 2018-01-03
HRP20211050T1 (hr) 2021-11-26
CA2976537C (en) 2024-05-28
JP6691922B2 (ja) 2020-05-13
US10294220B2 (en) 2019-05-21
EP3261644A4 (en) 2018-07-25
PT3261644T (pt) 2021-07-07
KR20170123320A (ko) 2017-11-07
AU2016225037B2 (en) 2021-06-17
EP3261644B1 (en) 2021-06-02
KR20210152580A (ko) 2021-12-15
JP2018506558A (ja) 2018-03-08
US20180044327A1 (en) 2018-02-15
EP4215527A1 (en) 2023-07-26
ES2879678T3 (es) 2021-11-22
EP3858826A1 (en) 2021-08-04
AU2021232790B2 (en) 2023-10-05
AU2021232790A1 (en) 2021-10-14
EP4215527B1 (en) 2024-10-09
AU2023229531A1 (en) 2023-09-28
FI4215527T3 (fi) 2024-12-19
PL3261644T3 (pl) 2021-10-25
AU2016225037A1 (en) 2017-09-07
KR102469789B1 (ko) 2022-11-23
DK3261644T3 (da) 2021-06-28
WO2016138425A1 (en) 2016-09-01
AU2023229531B2 (en) 2025-04-10
ES3010307T3 (en) 2025-04-02
CA2976537A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
IL278004A (en) Methods and preparations for treating conditions related to aging
PT4215527T (pt) Composições e métodos para tratar a degradação retinal
IL246791A0 (en) Compositions and methods for treating eye diseases
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
IL251759A0 (en) Preparations and methods for treating insomnia
PT3189074T (pt) Composições e métodos para tratar e prevenir a inflamação
IL256523A (en) Compositions and methods for treating cancer
IL255638A (en) Compositions and methods for treating cancer
IL251616A0 (en) Methods and compounds for the treatment and prevention of muscle loss
SG11201704829QA (en) Methods and compositions for treating brain diseases
SG11201606101WA (en) Compositions and methods for treating and preventing macular degeneration
IL254963A0 (en) Preparations and methods for the treatment of autism
IL253220A0 (en) Preparations and methods for the treatment of glaucoma
IL250114A0 (en) Methods and compositions for the treatment of hiv-related diseases
ZA201605109B (en) Compositions and methods for treating neutropenia
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
PT3519050T (pt) Composições para o tratamento de condições oftálmicas
IL256763A (en) Compositions and methods for treating cancer
IL252707B (en) Compositions and methods for treating diseases
PT3397270T (pt) Composições para utilização no tratamento da síndrome de hunter
EP3194446A4 (en) Compositions and methods for treating fibrosis
GB201521083D0 (en) Compositions for treatment and methods thereof
EP3259280A4 (en) Methods and compositions for treating glaucoma